Literature DB >> 32170698

Serum Virus Neutralization Assay for Detection and Quantitation of Serum Neutralizing Antibodies to Influenza A Virus in Swine.

Phillip C Gauger1, Amy L Vincent2.   

Abstract

The serum virus neutralization (SVN) assay is a serological test used to detect the presence and magnitude of functional systemic antibodies that prevent infectivity of a virus. The SVN assay is a highly sensitive and specific test that may be applied to influenza A viruses (IAV) in swine to measure the titer of neutralizing antibodies postexposure, postvaccination, or after passive transfer of maternally derived antibody (MDA). Conventional SVN methods performed in vitro are based on inhibition of virus infectivity in cell culture in the presence of neutralizing antibodies in serum. Titer determination may be based on the presence or absence of cytopathic effect or evidence of viral infection using an immunoreactive technique. The SVN assay is relatively inexpensive using standard laboratory equipment, although it requires cell culture, more time and labor, and technical skill to conduct the assay compared to other serological methods. The SVN test may be used to evaluate the level of serological cross-reactivity between IAV exposure or vaccine antisera and heterologous influenza viruses that may correlate with cross-protection in the host.

Entities:  

Keywords:  Antibody; Influenza; Serum; Swine; Titer; Virus neutralization

Mesh:

Substances:

Year:  2020        PMID: 32170698     DOI: 10.1007/978-1-0716-0346-8_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  Neuropathology of COVID-19 (neuro-COVID): clinicopathological update.

Authors:  Jerry J Lou; Mehrnaz Movassaghi; Dominique Gordy; Madeline G Olson; Ting Zhang; Maya S Khurana; Zesheng Chen; Mari Perez-Rosendahl; Samasuk Thammachantha; Elyse J Singer; Shino D Magaki; Harry V Vinters; William H Yong
Journal:  Free Neuropathol       Date:  2021-01-18

2.  An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees.

Authors:  Binjian Liu; Xibin Su; George Yu; Shuling Yang; Feng Wang; Tao Huang; Liuyong Zhou; Zhiqiang Hui; Yixian Liao; Yuan Qiu; Juan Huang; Hong Gao; Justin Liu; Yaoqi Zhong
Journal:  Int J Infect Dis       Date:  2021-12-10       Impact factor: 12.074

3.  A Single Vaccination of Chimeric Bivalent Virus-Like Particle Vaccine Confers Protection Against H9N2 and H3N2 Avian Influenza in Commercial Broilers and Allows a Strategy of Differentiating Infected from Vaccinated Animals.

Authors:  Yi-Xue Sun; Zheng-Rong Li; Peng-Ju Zhang; Jin-Hong Han; Hai-Yang Di; Jia-Yi Qin; Yan-Long Cong
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

4.  Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera.

Authors:  Henning Jacobsen; Ioannis Sitaras; Marley Jurgensmeyer; Mick N Mulders; David Goldblatt; Daniel R Feikin; Naor Bar-Zeev; Melissa M Higdon; Maria Deloria Knoll
Journal:  Vaccines (Basel)       Date:  2022-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.